Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0011849 (diabetes)
 277,896 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Serum fructosamine was determined in 115 diabetic patients with a C-Peptide secretion (0.84 +/- 0.06 pmol/ml, mean +/- SEM) (Group A) and in 30 type I C-peptide negative totally insulin-dependent subjects (less than 0.05 pmol/ml) (Group B). A significant correlation between fructosamine and HbA1 values (r = 0.70, p less than 0.001) was evidenced in Group A. In contrast, such a correlation was not found in Group B (r = 0.33, p greater than 0.05). Fructosamine levels were also in good agreement with the physician's ratings of the degree of glycemic control in Group A, but not in Group B. It is concluded that the fructosamine measurement represents a complement rather than an alternative to HbA1, in particular in unstable diabetic patients.
Diabetes Res 1987 Nov
PMID:Serum fructosamine level as a marker of glycemic control in diabetic patients with and without a residual C-peptide secretion. 343 13

It is important to identify diabetic patients in a coronary care population because they have a higher risk of suffering congestive heart failure, dysrhythmias and death following myocardial infarction. In order to determine the most efficient screening method for diabetes, we compared fructosamine and glucose measurements on admission blood specimens from 256 consecutive patients. Of 15 (5.9%) known diabetic patients, 12 had glucose results greater than or equal to 7.8 mmol/l and nine had fructosamine levels greater than 2.87 mmol/l. However, elevated glucose results were also found in a high proportion (49.2%) of patients with no previous history of diabetes. We performed glucose tolerance tests in 107 patients after discharge to determine the frequency of false-positive observations. Fructosamine yielded five (4.6%) false-positive results, whereas plasma glucose yielded 47 (43.9%) false-positive observations. We conclude that serum fructosamine provides a more specific screening method for diabetes in this population because the results are unaffected by stress hyperglycemia.
 ...
PMID:Serum fructosamine as a screening method for diabetes mellitus in patients with suspected acute myocardial infarction. 344 57

Serum fructosamine determination was evaluated in the assessment of glycaemic control in diabetes mellitus. Intra- and inter-assay variation of the method was 0.5-0.8 and 1.5-2.9%, respectively. The fructosamine concentration in serum was found to be stable for at least 10 days independent of prevailing serum glucose concentration is stored at +4 degrees C or colder. Stability of serum fructosamine with respect to rapid fluctuations of blood glucose was of the same order as that of HbA1c. The reference interval (mean +/- 2 SD) for 92 non-diabetic individuals was 1.9-2.7 mmol/l. Good correlation was found between HbA1c and serum fructosamine (r = 0.79). Serum fructosamine and HbA1c correlated well with the mean blood glucose values of the preceding week (r = 0.88 and 0.75, respectively, p less than 0.001). Significant correlations of fructosamine and HbA1c with fasting blood glucose were also found (r = 0.53 and 0.55, respectively, p less than 0.001). Fructosamine determined simultaneously with fasting blood glucose in 65 oral glucose tolerance tests (OGTT) did not separate normal subjects from those with impaired glucose tolerance. Two of the three subjects with diabetic response in the OGTT had, however, elevated fructosamine concentrations. Determination of serum fructosamine is a technically simple, reproducible and moderately inexpensive method for the assessment of glycaemic control in diabetes mellitus. Standardization of the method is, however, not without problems. Uniformity of the calibration and assay protocol is essential for reliable interlaboratory comparison of results. Physiological states altering the rate of synthesis or elimination of serum proteins should be considered in the interpretation of fructosamine levels.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Serum fructosamine in the assessment of glycaemic control in diabetes mellitus. 358 93

Serum fructosamine was compared with other measures of blood glucose control in 11 non-diabetic volunteers, 14 type 1 and 14 type 2 diabetic patients. Estimates of mean plasma glucose concentrations for the 28 diabetic patients were made by nine physicians, based on their interpretation of historical data, home capillary blood glucose profiles, fasting and random plasma glucose and plasma lipid levels. Significant differences between estimated and measured mean glucose levels were apparent with a tendency for physicians to underestimate mean blood glucose in the hyperglycaemic range (glucose greater than 11 mmol/l). Fructosamine results on the same patients correlated linearly both with mean plasma glucose concentrations (r = 0.86, p less than 0.001) and with glycosylated haemoglobin (HbA1c) levels (r = 0.93, p less than 0.001) and correctly classified diabetes control in most patients. Despite marked fluctuations of plasma glucose concentration, serum fructosamine levels measured at different times of the day did not alter significantly. We conclude that a random serum sample analysed for fructosamine provides a simple and reliable means to measure the efficacy of therapy and often provides information superior to clinical assessment of diabetic control.
 ...
PMID:Serum fructosamine in patients with diabetes mellitus. 386 65

Serum fructosamine activity was studied in 42 patients with type I (insulin dependent) diabetes mellitus and 30 non-diabetic volunteers as an index of blood glucose control. There was a significant correlation both between fructosamine and glycosylated haemoglobin values (r = 0.82) and between fructosamine and the fasting C peptide concentration (r = -0.81). Test results in 14 of the diabetics reflected the mean plasma glucose concentration calculated from 25 serial estimations in a single 24 hour period (r = 0.75; p less than 0.01) but not the mean amplitude of glycaemic excursion (r = 0.23; p greater than 0.05). Fructosamine concentrations measured in these multiple blood specimens did not change significantly throughout the day (mean coefficient of variation 4.1%) despite wide variability of the respective plasma glucose concentrations (mean coefficient of variation 36.2%). It is concluded that a single random serum sample analysed for fructosamine concentration provides a simple and reliable assessment of glucose homoeostasis in patients with type I diabetes mellitus.
 ...
PMID:Serum fructosamine concentration as measure of blood glucose control in type I (insulin dependent) diabetes mellitus. 391 16

We have developed an automated colorimetric assay for glycated serum proteins (or fructosamines), measuring the reducing activity of serum in alkaline solution (pH 10.35) at 37 degrees C. The calibrants were prepared from a synthetic fructosamine (1-deoxy-1-morpholinofructose), although secondary standards of glycated bovine albumin were more robust in routine application. Interference was appreciable only with icteric specimens (bilirubin greater than 60 mumol/L), and between-batch imprecision (CV) was less than 2%. The range of fructosamine concentrations measured in 502 healthy (nondiabetic) blood donors was 1.87-2.87 mmol/L. There were no significant (p greater than 0.05) age- or sex-related differences in this population sample. Fructosamine accurately reflected blood glucose control as evidenced by the significant correlation with glucose concentrations in fasting plasma (r = 0.82, p less than 0.001) and with glycated hemoglobin (HbA1c) (r = 0.87, p less than 0.01) in 115 patients with type 2 (non-insulin-dependent) diabetes mellitus. The test is simple and rapid to perform (75 samples per hour) and provides an alternative to HbA1c determinations for monitoring blood glucose control and assessing the effects of changes in diabetes management.
 ...
PMID:Use of protein-based standards in automated colorimetric determinations of fructosamine in serum. 402 2

Fructosamine, an indicator of glycosylated serum protein, was measured in 79 non-diabetic pregnant women and 20 women with gestational diabetes. The test provided a clear discrimination between groups; it detected 17 (85%) of the women with gestational diabetes and gave only 4 (5%) false-positive results. 19 women with established diabetes before pregnancy had very high levels. Maternal fructosamine at 29 weeks' gestation correlated significantly with both fasting blood glucose levels at the time and birthweight ratio. Levels of fructosamine in cord blood were significantly higher in gestational diabetic than in normal pregnancies, suggesting a possible additional role for fructosamine in retrospectively detecting the hyperglycaemic fetus. Fructosamine estimation is fully automated and may provide a simple, inexpensive means to screen for diabetes in pregnancy.
 ...
PMID:Fructosamine in diabetic pregnancy. 613 96

Fructosamine, a putative measure of serum glycosylated proteins, was measured in 74 subjects referred for oral glucose tolerance tests. A normal range (mean (2 SD] of 1.6 (0.4) mmol/l (40(10) mg/100 ml) derive from results obtained in 83 healthy non-diabetic volunteers permitted the detection of 15 out of 17 (88%) subjects with proved diabetes and yielded only five (9%) false positive diagnoses. Fructosamine concentrations correlated significantly (p less than 0.001) with fasting plasma glucose concentrations (r = 0.76) and glycosylated haemoglobin concentrations (r = 0.70). A longitudinal study suggested that fructosamine concentration was an index of intermediate term (one to three weeks) blood glucose control. Fructosamine concentration was not related to uraemia and did not depend on albumin or total protein concentrations, provided that serum albumin concentrations remained above 30 g/l. Estimation of fructosamine concentrations is a fully automated procedure and may provide a simple means of screening for diabetes mellitus.
 ...
PMID:Clinical usefulness of estimation of serum fructosamine concentration as a screening test for diabetes mellitus. 641 61

Three groups of 10 age- and sex-matched nondiabetic volunteers took 0, 750, or 1500 mg of vitamin C each day for 12 weeks. Glycohemoglobin (GHb) was measured by HPLC, electrophoresis, affinity chromatography, and immunoassay at baseline (-4 weeks and -1 day), during supplementation (6 weeks and 12 weeks), and after supplementation ended (6 and 12 weeks). Plasma vitamin C increased twofold during supplementation but, in contrast with the results of Davie et al. (Diabetes 1992; 41:167-73), there were no between-group differences in GHb, glucose, and fructosamine concentrations. Fructosamine may have increased with storage time. The net effects of vitamin C on absolute GHb at 12 weeks vs -1 day (and at 12 weeks vs 12 weeks after) in % GHb amounted to: HPLC -0.035 (-0.050); electrophoresis +0.005 (+0.035); affinity chromatography -0.070 (+0.015); and immunoassay -0.110 (+0.025). We conclude that supplementation of nondiabetics with 750 or 1500 mg of vitamin C daily for 12 weeks does not cause interference in GHb determinations by HPLC, electrophoresis, affinity chromatography, or immunoassay, and does not reduce in vivo Hb glycation.
 ...
PMID:Vitamin C and glycohemoglobin. 772 50

Blood serum fructosamine level were measured on an empty stomach in 97 normal subjects and subjects with various disorders of carbohydrate metabolism (the so-called "pre-diabetes" and changed glucose tolerance) in order to elucidate the significance of this factor as a marker of such disorders. Fructosamine concentrations were for the first time measured in children whose parents suffered from insulin-dependent or noninsulin-dependent diabetes mellitus. The content of fructosamine on an empty stomach was found to depend on the degree of carbohydrate metabolism disorders, increasing with the progress of these disorders. The findings permit a conclusion on the possibility of using fructosamine as a marker for the diagnosis of "pre-diabetes" in subjects with its levels of 2.5 to 2.99 mmol/l and of disordered glucose tolerance in those with its levels over 3 mmol/l and glucose level on an empty stomach no more than 6 mmol/l.
 ...
PMID:[Determination of fructosamine in the early diagnosis of disorders of carbohydrate metabolism]. 774 29


<< Previous 1 2 3 4 5 6 7 8 9 Next >>